Original Article
Neuropsychopharmacology (2004) 29, 826–832, advance online publication, 18 February 2004; doi:10.1038/sj.npp.1300399
Amygdala Volume Reductions in Pediatric Patients with Obsessive–Compulsive Disorder Treated with Paroxetine: Preliminary Findings
Philip R Szeszko1,2, Shauna MacMillan3, Marjorie McMeniman1,2, Elisa Lorch3, Rachel Madden3, Jennifer Ivey3, S Preeya Banerjee3, Gregory J Moore3,4 and David R Rosenberg3,5
- 1Department of Psychiatry Research, Zucker Hillside Hospital, North Shore - Long Island Jewish Health System, Glen Oaks, NY, USA
- 2Department of Psychiatry, Albert Einstein College of Medicine, Bronx, NY, USA
- 3Departments of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA
- 4Department of Radiology, Wayne State University School of Medicine, Detroit, MI, USA
- 5Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA
Correspondence: Dr PR Szeszko, Zucker Hillside Hospital, Department of Psychiatry Research, 75-59 263rd Street, Glen Oaks, NY 11004, USA. Tel: +1-718-470-8489; Fax: +1-718-343 1659; E-mail: szeszko@lij.edu
Received 18 June 2003; Revised 24 October 2003; Accepted 31 December 2003; Published online 18 February 2004.
Abstract
The amygdala is believed to be highly relevant to the pathophysiology of obsessive–compulsive disorder (OCD) given its prominent role in fear conditioning and because it is an important target of the serotonin reuptake inhibitors (SRIs), the pharmacotherapy of choice for OCD. In the present study, we measured in vivo volumetric changes in the amygdala in pediatric patients with OCD following 16 weeks of monotherapy with the selective SRI, paroxetine hydrochloride. Amygdala volumes were computed from contiguous 1.5 mm magnetic resonance (MR) images in 11 psychotropic drug-naive patients with OCD prior to and then following treatment. Eleven healthy pediatric comparison subjects also had baseline and follow-up scans, but none of these subjects received medication. Patients demonstrated significant asymmetry of the amygdala (L>R) prior to pharmacologic intervention in contrast to healthy comparison subjects who showed no asymmetry at the time of their baseline scan. Mixed model analyses using age and total brain volume as time varying covariates indicated that left amygdala volume decreased significantly in patients following treatment. The reduction in left amygdala volume in patients correlated significantly with higher paroxetine dosage at the time of the follow-up scan and total cumulative paroxetine exposure between the scans. No significant changes in either right or left amygdala volume were evident among healthy comparison subjects from the baseline to the follow-up scan. These preliminary findings suggest that abnormal asymmetry of the amygdala may play a role in the pathogenesis of OCD and that paroxetine treatment may be associated with a reduction in amygdala volume.
Keywords:
obsessive–compulsive disorder, magnetic resonance imaging, amygdala, paroxetine
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Glutamatergic Dysfunction in OCD
Neuropsychopharmacology Original Article
Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive?Compulsive Disorder
Neuropsychopharmacology Original Article
Fluvoxamine Treatment and D2 Receptors: a Pet Study on OCD Drug-Na???ve Patients
Neuropsychopharmacology Original Article
Neuropsychopharmacology Original Article

